Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients-Reference-Cited by-同舟云学术

Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients

Published:2013-03-27 Issue:7 Volume:34 Page:1628-1636
ISSN:0172-0643
Container-title:Pediatric Cardiology
language:en
Short-container-title:Pediatr Cardiol

Author:

Maxey Dawn M.,Ivy D. Dunbar,Ogawa Michelle T.,Feinstein Jeffrey A.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Pediatrics, Perinatology and Child Health

Link

http://link.springer.com/content/pdf/10.1007/s00246-013-0688-2.pdf

Reference10 articles.

1. Abman S (2010) Pulmonary hypertension in children: a historical overview. Pediatr Crit Care Med 11(2 Suppl):S4–S9

2. Adverse Event Reporting System (AERS) (2006) Background report definitions, and caveats. Department of Health and Human Services

3. Barst RJ et al (2006) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28:1195–1203

4. Barst RJ, Layton G, Konourina I, Richardson H, Beghetti M, Ivy DD (2012) STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive patients with pediatric pulmonary arterial hypertension. Eur Heart J 33(Suppl 1):979

5. Barst RJ et al (2012) A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125:324–334

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural ingredients from Chinese materia medica for pulmonary hypertension;Chinese Journal of Natural Medicines;2021-11

2. Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions;Clinical Pharmacology in Drug Development;2021-08-27

3. Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment;Comprehensive Physiology;2021-06-30

4. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues – a single‐centre experience;Pulmonary Circulation;2021-01

5. Drug Treatment of Pulmonary Hypertension in Children;Pediatric Drugs;2020-01-21